JP2022505471A5 - - Google Patents

Info

Publication number
JP2022505471A5
JP2022505471A5 JP2021521516A JP2021521516A JP2022505471A5 JP 2022505471 A5 JP2022505471 A5 JP 2022505471A5 JP 2021521516 A JP2021521516 A JP 2021521516A JP 2021521516 A JP2021521516 A JP 2021521516A JP 2022505471 A5 JP2022505471 A5 JP 2022505471A5
Authority
JP
Japan
Prior art keywords
alkyl
independently
substituted
formula
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021521516A
Other languages
English (en)
Japanese (ja)
Other versions
JP7480135B2 (ja
JP2022505471A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/057260 external-priority patent/WO2020086481A1/en
Publication of JP2022505471A publication Critical patent/JP2022505471A/ja
Publication of JP2022505471A5 publication Critical patent/JP2022505471A5/ja
Application granted granted Critical
Publication of JP7480135B2 publication Critical patent/JP7480135B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021521516A 2018-10-21 2019-10-21 新規使用 Active JP7480135B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748517P 2018-10-21 2018-10-21
US62/748,517 2018-10-21
PCT/US2019/057260 WO2020086481A1 (en) 2018-10-21 2019-10-21 Novel uses

Publications (3)

Publication Number Publication Date
JP2022505471A JP2022505471A (ja) 2022-01-14
JP2022505471A5 true JP2022505471A5 (https=) 2022-10-28
JP7480135B2 JP7480135B2 (ja) 2024-05-09

Family

ID=70331921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521516A Active JP7480135B2 (ja) 2018-10-21 2019-10-21 新規使用

Country Status (11)

Country Link
US (2) US12194042B2 (https=)
EP (1) EP3866808A4 (https=)
JP (1) JP7480135B2 (https=)
KR (1) KR20210080418A (https=)
CN (1) CN113194955A (https=)
AU (1) AU2019364274C1 (https=)
BR (1) BR112021007571A2 (https=)
CA (1) CA3117148A1 (https=)
IL (1) IL282396A (https=)
MX (1) MX2021004531A (https=)
WO (1) WO2020086481A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210614A1 (en) * 2019-04-12 2020-10-15 Intra-Cellular Therapies, Inc. Organic compounds
EP4413980A3 (en) 2019-09-03 2024-10-30 Intra-Cellular Therapies, Inc. Novel compounds
MX2023008755A (es) * 2021-01-27 2023-08-02 Intra Cellular Therapies Inc Cristales de sal.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2465893A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
RS52166B (sr) 2007-05-11 2012-08-31 Pfizer Inc. Amino-heterociklična jedinjenja
KR20120012831A (ko) 2007-12-06 2012-02-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
TW201206937A (en) * 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
US10918628B2 (en) * 2016-10-11 2021-02-16 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Treatment of synucleinopathies

Similar Documents

Publication Publication Date Title
RU2317817C2 (ru) Применение (1s,2r) энантиомера милнаципрана для получения лекарственного средства
RU2485943C2 (ru) Бупропиона гидробромид и его терапевтические применения
JP2022505471A5 (https=)
TWI335217B (en) Pharmaceutical formulations of modafinil
RU2006141416A (ru) Пролекарства леводопа, композиции на их основе и их применения
EP1641461B1 (fr) Association d'un antagoniste ou agoniste inverse du recepteur h3 de l'histamine avec un anti-psychotique ou un antidepresseur et son utilisation pour preparer un medicament prevenant des effets indesirables de medicaments psychotropes
TW200808696A (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8729120B2 (en) Adjunctive therapy for depression
Sanford et al. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson’s disease
RU97119427A (ru) Сочетание ингибитора усвоения 5-нт с селективным 5-нтia антагонистом
RU2006107534A (ru) Комбинация, включающая альфа-2-дельта-лиганд анд и ssri и/или snri, для лечения депрессии и тревожного расстройства
Sekar et al. An overview of the role of monoamine oxidase-B in Parkinson’s disease: Implications for neurodegeneration and therapy
MX2008000249A (es) Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
US20210379072A1 (en) Novel uses
JP2006505548A (ja) Pparリガンドと抗酸化剤の会合および肥満の治療のためのその使用
RU2021114144A (ru) Новые применения
JP2015529196A5 (https=)
TW201412304A (zh) 瑞沙吉林之非經腸調配物
EP2504006B1 (en) Compositions comprising amino acids for treating chronic obstructive pulmonary disease
JP2012184263A (ja) 脳梗塞に関連する脳血管障害の治療に有用なピラゾロン化合物
JP2002511408A (ja) 神経疾患のための新しい治療
JP2024510021A (ja) タシピミジン製剤およびその使用
AU2006209368B2 (en) New association between agomelatine and a noradrenaline reuptake inhibitor and pharmaceutical compositions containing it
JP2021529826A (ja) ブプロピオンを用いてテトラベナジン代謝物の血漿濃度を調節する方法
Suvar Antidepressants